DreaMed Diabetes Overview
Founded in 2014, DreaMed pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the world’s first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps. DreaMed's mission is to unlock and scale medical knowledge so that every person living with diabetes can access personalized, expert-level care when and where it’s needed. We strive to achieve this mission by creating software that uses advanced AI and analytics to transform the massive amounts of patient data available into expert-level treatment recommendations, and to do this at a global scale. DreaMed’s product, endo.digital, is a cloud-based SAAS platform that gives healthcare organizations an end-to-end diabetes care pathway solution that can be deployed across all care settings where patients with diabetes are treated, both remotely and in person. It is the only decision support software cleared by the FDA to support both Type 1 and Type 2 diabetes. DreaMed's founders are physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards.
Cumulative Funding Raised Over Time ($)
$2.2MApr 2015
$5.2MAug 2024
$6.3MJan 2021
$10.7MJul 2016
Latest News
growth-positive
DreaMed secures $3M and strategic deals amid CEO's reserve IDF duty | CTech
Israeli startup DreaMed Diabetes has raised $3 million in a funding round led by VC eHealth Ventures. The company has developed an AI-based platform, endo.digital, which provides treatment recommendations for people with diabetes. The funds will be used to further commercialize DreaMeds solution. The company has also signed several deals with health systems and companies, including a data integration agreement with Abbott, a leading medical device company in the diabetes sector. DreaMed has also signed agreements with prominent health systems in the U.S., including Yale New Haven Health, and is planning to re-establish its U.S. branch.
InvestmentPartnersExpand
https://dreamed.ai/abbotts-freestyle-libre-data-now-integrates-into-endo-digital-platform/
Yale New Haven Health frees up 9 minutes per patient visit with DreaMed’s EMR integrated deployment
Billings Clinic endocrinology increases CGM 95251 revenue by 60% with the endo.digital platform
DreaMed receives 5th FDA Clearance
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $16.8M |
| Last funding | $3M |
| Stage | Seed |
| Rounds | 6 |
| Investors | 5 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | dreamed.ai/ |
| Careers | Careers page |
| Google Play | Google Play |
Locations
Atir Yeda St 1, Kefar Sava, 4464301, Israel
Photos & Videos
3 item(s)
DreaMed Diabetes Business
Business models
B2B2C, B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareInsurance CompaniesProvidersPatientsCore Technology
Data StorageCloudArtificial IntelligenceSensingTags (19)
digital-healthcaremonitoringdiabetesdata-analyticsremote-monitoringdecision-makingreal-timetelemedicinehealthcare-providerssensorscloudactionable-insightstelehealthartificial-intelligencechronic-patientspersonalizationtreatmentsinsurance-companiesdecision-supportGeographic Markets
IsraelUnited StatesDreaMed Diabetes Financials
$16.8M
Total funding
Undisclosed
Capital raised
$3M
Last funding
Seed
Funding stage
6
Total rounds
5
Investors
Cumulative Funding Raised Over Time ($)
$2.2MApr 2015
$5.2MAug 2024
$6.3MJan 2021
$10.7MJul 2016
Private Equity Funding
Seed
Aug 2024
$3M
eHealth Ventures (Lead)
,
OurCrowd
SAFE
Jan 2021
$1.1M
Undisclosed Investor(s)
Pre-Seed
Jul 2016
$4.4M
Medtronic, OurCrowd, Norma Investments
Pre-Seed
Apr 2015
$2.2M
Medtronic
Non-Equity Funding
GrantEvent
Jan 2022
$2.7M
Helmsley Charitable Trust
GrantEvent
Mar 2016
$3.4M
Helmsley Charitable Trust
DreaMed Diabetes Lifecycle
Cumulative Funding Raised Over Time
$2.2MApr 2015
$5.2MAug 2024
$6.3MJan 2021
$10.7MJul 2016
All Events
Seed
Aug 2024
$3M
eHealth Ventures (Lead)
,
OurCrowd
SAFE
Jan 2021
$1.1M
Undisclosed Investor(s)
Pre-Seed
Jul 2016
$4.4M
Medtronic, OurCrowd, Norma Investments
Pre-Seed
Apr 2015
$2.2M
Medtronic
GrantEvent
Jan 2022
$2.7M
Helmsley Charitable Trust
GrantEvent
Mar 2016
$3.4M
Helmsley Charitable Trust
DreaMed Diabetes News
27 articles
growth-positive
DreaMed secures $3M and strategic deals amid CEO's reserve IDF duty | CTech
Israeli startup DreaMed Diabetes has raised $3 million in a funding round led by VC eHealth Ventures. The company has developed an AI-based platform, endo.digital, which provides treatment recommendations for people with diabetes. The funds will be used to further commercialize DreaMeds solution. The company has also signed several deals with health systems and companies, including a data integration agreement with Abbott, a leading medical device company in the diabetes sector. DreaMed has also signed agreements with prominent health systems in the U.S., including Yale New Haven Health, and is planning to re-establish its U.S. branch.
InvestmentPartnersExpand
https://dreamed.ai/abbotts-freestyle-libre-data-now-integrates-into-endo-digital-platform/
Yale New Haven Health frees up 9 minutes per patient visit with DreaMed’s EMR integrated deployment
Billings Clinic endocrinology increases CGM 95251 revenue by 60% with the endo.digital platform
DreaMed receives 5th FDA Clearance
growth-positive
DreaMed partners with Billings Clinic to bring personalized expert level diabetes care to Montana's health network
DreaMed Diabetes partners with Billings Clinic to deploy its AI-based clinical decision support system for diabetes treatment. The system aims to address the shortage of endocrinologists and improve access to expert-level care, particularly in rural areas like Montana. Billings Clinic will initially deploy the technology in its endocrinology clinic and plans to expand its use into primary care and other healthcare settings. The partnership is seen as a positive growth opportunity for DreaMed Diabetes.
PartnersCustomers
University of Colorado School of Medicine Will Work with DreaMed Diabetes to Deploy Its Advisor System as a New Resource for Diabetes Device Initiation
DreaMed Diabetes' 'digital endocrinologist' AI expands to Type 2 diabetes with FDA green light
DreaMed Receives FDA Clearance for its Type 2 Diabetes AI-based Clinical Decision Support System
growth-positive
https://www.healthcareglobal.com/telehealth-and-covid-19/dreameds-ai-solution-diabetes-expands-across-us
DreaMed Diabetes, an AI-based remote diabetes solution, has received FDA approval and will be made available in clinics across the US, with a focus on rural communities. The cloud-based tool uses AI to monitor glucose levels and lifestyle habits, providing clinicians with a thorough analysis of patient data. It aims to enable remote treatment and has been found to be as effective as human-managed treatment programs. With the US healthcare system under pressure due to the pandemic and diabetes increasing the risk of mortality in COVID-19 patients, tech companies are offering telehealth solutions to ease the burden on healthcare staff. DreaMed Diabetes will be implemented in clinics across the country, including Lucile Packard Children’s Hospital Stanford, the Billings Clinic, Hassenfeld Children’s Hospital at NYU Langone, and University of Florida Health.
CustomersPartners
growth-positive
AI-based decision support tool optimizes insulin use for youths with type 1 diabetes
A randomized controlled trial showed that an automated decision support tool for optimizing insulin pump settings, the DreaMed Advisor Pro, was noninferior to intensive insulin titration provided by physicians. The tool uses artificial intelligence to analyze glucose patterns and insulin dosing events and makes recommendations to improve diabetes control. The study found that the tool was as effective and safe as physicians in controlling glucose levels. It can free up providers time and be used in tandem with telemedicine approaches to deliver expert knowledge and reduce disease burden for patients. The tool could also lower costs associated with clinical visits and overcome missed visits, particularly in rural areas or during circumstances like COVID-19.
Customers
Nature Medicine Publishes Results Reporting Equal Clinical Outcome When Using The DreaMed Advisor® Compared With Physicians From Specialized Academic Diabetes Centers
https://www.morningstar.com/news/business-wire/20200824005135/amid-north-america-push-dreamed-appoints-new-general-manager
growth-positive
DreaMed to Participate in $5Million Study for Virtual Healthcare for Diabetic Patients
DreaMed Diabetes, a developer of AI-based diabetes healthcare and management solutions, will be participating as a subcontractor in a study conducted by the Jaeb Center for Health Research Foundation. The foundation has received a $5 million funding from The Leona M. and Harry B. Helmsley Charitable Trust. The study aims to evaluate the effectiveness of telemedicine in diabetes management and will involve 300 participants over six months. DreaMed will provide personalized recommendations on insulin dosages using their DreaMed Advisor Platform.
Investment
Hillel's Tech Corner: DreaMed Diabetes: Optimizing treatment
Amid COVID-19 Pandemic, DreaMed Diabetes Announces Implementation of Its Advisor Pro Software at Top-rated U.S. Children's Hospital
growth-positive
DreaMed Launches Virtual Diabetes Clinic to Help Type-1 Diabetics Control Their Condition in Quarantine
DreaMed Diabetes has launched a virtual diabetes clinic to treat people with type 1 diabetes remotely. The clinic utilizes AI-powered technology to analyze insulin and glucose data and provide remote advice to doctors. This is particularly important during the COVID-19 pandemic, as people with chronic medical conditions, including diabetes, are at higher risk of complications. The virtual clinic allows patients to access medical professionals without the need for in-person visits, ensuring their treatment remains unaffected by quarantines. DreaMed Diabetes aims to provide reliable and automated decision support to healthcare professionals and empower patients with the best care possible.
Customers
Dexcom and DreaMed Diabetes Announce Collaboration to Integrate Dexcom CGM Data into DreaMed Advisor
growth-positive
Cracking the Code: CEO Eran Atlas Talks DreaMed's Revolutionary Tech
The article discusses the founding and development of DreaMed Diabetes, a company that focuses on developing technology solutions for people with diabetes. The company has partnered with Medtronic Diabetes and has made a licensing deal with them. They have developed a decision support system called DreaMed Advisor, which provides personalized insulin delivery recommendations based on data from continuous glucose monitors. The company aims to expand its technology to reach more users, including those on multiple daily injections and those with type 2 diabetes. They are also working on finding the right commercial model to make their technology accessible to more patients. The article emphasizes the importance of involving healthcare providers in patient care and the need to make top-tier treatment accessible to everyone.
Partners
growth-positive
New FDA Clearance Paves The Way to Optimization of Insulin Pump Therapy Across All Glucose Measurement Methods
DreaMed Diabetes has received FDA clearance and CE Mark for its artificial intelligence-based insulin dosing decision support software, DreaMed Advisor Pro. The software is designed for people with Type 1 diabetes using insulin pump therapy with continuous glucose sensors and/or blood glucose meters. It analyzes data from CGMs, self-monitoring blood glucose, and insulin pump data to generate insulin delivery recommendations. The software has already been incorporated as a decision support system in several US clinics. DreaMed Diabetes aims to become the standard-of-care for optimizing insulin therapy for people with Type 1 and Type 2 diabetes. Investors in the company include Medtronic Diabetes, Norma Investments, and OurCrowd.
Customers
growth-positive
T1D Exchange and DreaMed Diabetes Formalize Partnership to Optimize Insulin Treatment Plans in Clinics BioSpace
T1D Exchange has partnered with DreaMed Diabetes to provide six clinics in its Quality Improvement Collaborative (QIC) with access to DreaMed Advisor Pro, an AI-based decision support technology. The partnership aims to help high-risk patients achieve optimal treatment for maintaining balanced glucose levels. T1D Exchange plans to expand its clinical success in the US to international partners. DreaMed Advisor Pro analyzes patient data from various devices to determine insulin delivery recommendations. The partnership will allow T1D Exchange and DreaMed to analyze patient outcomes and gain insight into the impact of the software on clinics and their patients. The T1D Exchange QIC is supported by The Leona M. and Harry B. Helmsley Charitable Trust, and DreaMed Diabetes is backed by Medtronic Diabetes, Norma Investments, and OurCrowd.
PartnersCustomers
BIOCORP and DreaMed Diabetes Join to Offer an Outstanding AI System for Diabetes Treatment Compliance
growth-positive
DreaMed Diabetes Granted FDA Authorization to Market Advisor Pro, Offering Personalized Optimization of Insulin Pump Therapy
DreaMed Diabetes has received FDA approval for its artificial intelligence-based diabetes treatment decision support software, DreaMed Advisor Pro. The software is designed to assist healthcare providers in managing people with type 1 diabetes who use insulin pumps and continuous glucose monitoring. Advisor Pro analyzes data from CGM, self-monitoring blood glucose, and insulin pump data to generate insulin delivery recommendations. The approval is seen as a significant achievement in the field of AI and digital health, and it is expected to improve patient care and outcomes for people with type 1 diabetes. DreaMed Diabetes has also received regulatory approval in the EU and has partnered with Glooko for integration into their diabetes data management platform.
Customers
growth-positive
DreaMed Diabetes Receives CE Mark for Platform for the Management of Type 1 Diabetes
DreaMed Diabetes, a developer of diabetes management solutions, has received CE Mark for its Advisor Pro decision-support platform. The platform assists healthcare professionals in managing Type 1 diabetes. The cloud-based solution offers a personalised insulin treatment plan based on the analysis of data from a variety of sources. The company is currently conducting a multi-center clinical study for Advisor Pro in partnership with Glooko, a leader in mobile and web applications for diabetes management. The study aims to assess the ability of Advisor Pro to adjust blood glucose levels and prevent hypoglycemic events.
PartnersCustomers
growth-positive
U.S. and Israeli researchers collaborate to improve insulin management for people with type 1 diabetes
Harvard SEAS has entered a research collaboration agreement with DreaMed Diabetes and Schneider Children’s Medical Center to optimize therapy options for patients with type 1 diabetes who receive multiple daily injections of insulin and use point of care capillary glucose measurements.
Partners
growth-positive
DreaMed Diabetes raises $3.3m from Roman Abramovich
Israeli startup DreaMed Diabetes has raised $3.3 million in funding from Norma Investments Limited and a strategic investor. The funds will be used to further develop the companys decision support technology platform for optimal insulin treatment plans. DreaMed Diabetes aims to create easy-to-use and intelligent systems for diabetes treatment and management. The company plans to broaden the application of its Advisor platform for physicians and people with diabetes who rely on multiple daily injections or insulin pumps.
Investment
growth-positive
Medtronic teams with DreaMed Diabetes on artificial pancreas
Medtronic has invested $2 million in Israeli company DreaMed Diabetes and signed a development and marketing deal with it. DreaMed has developed a technology that connects continuous insulin sensors with insulin pumps. Medtronic will integrate DreaMeds program into its diabetes products and will pay DreaMed royalties for each product sold. The technology is already approved for marketing in Europe, and Medtronic will seek to obtain a license for the product and the program from the regulatory authorities in the EU and the US.
InvestmentPartners
DreaMed Diabetes Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 50 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.
DreaMed Diabetes Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 101/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515052520 |
| Crunchbase | dreamed-diabetes |
| Phone | 0502428305 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-03T00:00:00.000Z |
| Created | 2014-08-06T00:00:00.000Z |
| Claimed | Yes |